KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Gains from Sales and Divestitures (2018 - 2020)

Esperion Therapeutics (ESPR) has disclosed Gains from Sales and Divestitures for 3 consecutive years, with $53587.0 as the latest value for Q2 2020.

  • For the quarter ending Q2 2020, Gains from Sales and Divestitures rose 427.95% year-over-year to $53587.0, compared with a TTM value of $53587.0 through Jun 2020, up 427.95%, and an annual FY2019 reading of $17710.0, up 415.27% over the prior year.
  • Gains from Sales and Divestitures was $53587.0 for Q2 2020 at Esperion Therapeutics, up from $10089.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $53587.0 in Q2 2020 and bottomed at $1562.0 in Q1 2018.
  • Average Gains from Sales and Divestitures over 3 years is $11850.9, with a median of $6763.0 recorded in 2018.
  • The sharpest move saw Gains from Sales and Divestitures skyrocketed 100.06% in 2019, then surged 427.95% in 2020.
  • Year by year, Gains from Sales and Divestitures stood at $3437.0 in 2018, then skyrocketed by 415.27% to $17710.0 in 2019, then skyrocketed by 202.58% to $53587.0 in 2020.
  • Business Quant data shows Gains from Sales and Divestitures for ESPR at $53587.0 in Q2 2020, $10089.0 in Q1 2020, and $17710.0 in Q4 2019.